0 code page views remaining today. Guest accounts are limited to 2 daily page views. Register free account to get more views.
Log in Register free account

Official Description

Chemotaxis assay, specify method

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86155 refers to a chemotaxis assay, which is a laboratory test that evaluates the movement of white blood cells (leukocytes) in response to chemical signals released from injured or diseased tissues. This assay is significant in assessing immune function and monitoring cancer progression, as it provides insights into how effectively the immune system can respond to pathological conditions. During the procedure, a blood sample is collected, and various methods can be employed to analyze the chemotactic response of the white blood cells. It is essential to specify the method used for the assay, as different techniques may yield varying results. Qualitative tests may utilize aggregation methods or T-maze adaptations designed for microplate formats, allowing for the observation of cell behavior in response to stimuli. Alternatively, semi-quantitative tests may involve overlaying the cells on a specific substrate and measuring changes in opalescence, which indicates the degree of cell migration. Overall, the chemotaxis assay is a valuable tool in clinical settings for understanding immune responses and the dynamics of disease progression.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The chemotaxis assay (CPT® Code 86155) is indicated for various clinical scenarios where the evaluation of immune function is necessary. The following conditions may warrant the use of this assay:

  • Immune Dysfunction The assay is utilized to assess the functionality of the immune system, particularly in patients with suspected immune deficiencies or disorders.
  • Cancer Progression It is employed to monitor the progression of cancer, as changes in white blood cell response can indicate tumor activity or metastasis.
  • Infectious Diseases The test may be indicated in cases of infections where the immune response is critical for recovery, helping to evaluate the effectiveness of the immune response to pathogens.

2. Procedure

The procedure for conducting a chemotaxis assay involves several key steps that ensure accurate measurement of white blood cell migration in response to chemical signals. The following outlines the procedural steps:

  • Step 1: Sample Collection A blood sample is drawn from the patient, typically using venipuncture. This sample serves as the source of white blood cells needed for the assay.
  • Step 2: Cell Isolation The white blood cells are isolated from the blood sample through centrifugation or other separation techniques, ensuring that the cells are concentrated for the assay.
  • Step 3: Method Specification The specific method for the chemotaxis assay is selected and specified. This could involve qualitative methods such as aggregation or T-maze adaptations, or semi-quantitative methods that measure changes in opalescence.
  • Step 4: Assay Execution The isolated white blood cells are then exposed to a test substrate or chemical attractants in a controlled environment. The response of the cells is monitored, and their migration patterns are recorded.
  • Step 5: Data Analysis The results of the assay are analyzed to determine the degree of chemotaxis, which provides insights into the immune response and potential pathological conditions.

3. Post-Procedure

After the chemotaxis assay is completed, the results are compiled and interpreted by laboratory professionals. The findings can provide valuable information regarding the patient's immune function and disease status. There are typically no specific post-procedure care requirements for patients, as the assay is performed in a laboratory setting and does not involve invasive techniques. However, it is essential for healthcare providers to discuss the results with the patient and consider any further diagnostic or therapeutic actions based on the assay outcomes.

Short Descr CHEMOTAXIS ASSAY
Medium Descr CHEMOTAXIS ASSAY SPECIFY METHOD
Long Descr Chemotaxis assay, specify method
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 235 - Other Laboratory
Date
Action
Notes
Pre-1990 Added Code added.